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Kristina B Kristoffersen6, Long Wei7, Olaf Burkhardt8, Tobias Welte8, Stefan Schroeder9, Vandack Nobre10,
Michael Tamm4, Neera Bhatnagar11, Heiner C Bucher2, Charles-Edouard Luyt12, Jean Chastre12, Florence Tubach13,
Beat Mueller1 and Philipp Schuetz1*Abstract
Introduction: Whether the inflammatory biomarker procalcitonin provides prognostic information across clinical
settings and different acute respiratory tract infections (ARIs) is poorly understood. In the present study, we
investigated the prognostic value of admission procalcitonin levels to predict adverse clinical outcome in a large
ARI population.
Methods: We analysed data from 14 trials and 4,211 ARI patients to study associations of admission procalcitonin
levels and setting specific treatment failure and mortality alone at 30 days. We used multivariable hierarchical
logistic regression and conducted sensitivity analyses stratified by clinical settings and ARI diagnoses to assess the
results’ consistency.
Results: Overall, 864 patients (20.5%) experienced treatment failure and 252 (6.0%) died. The ability of procalcitonin
to differentiate patients with from those without treatment failure was highest in the emergency department
setting (treatment failure area under the curve (AUC): 0.64 (95% confidence interval (CI): 0.61, 0.67), adjusted odds
ratio (OR): 1.85 (95% CI: 1.61, 2.12), P <0.001; and mortality AUC: 0.67 (95% CI: 0.63, 0.71), adjusted OR: 1.82 (95% CI:
1.45, 2.29), P <0.001). In lower respiratory tract infections, procalcitonin was a good predictor of identifying patients
at risk for mortality (AUC: 0.71 (95% CI: 0.68, 0.74), adjusted OR: 2.13 (95% CI: 1.82, 2.49), P <0.001). In primary care
and intensive care unit patients, no significant association of initial procalcitonin levels and outcome was found.
Conclusions: Admission procalcitonin levels are associated with setting specific treatment failure and provide the
most prognostic information regarding ARI in the emergency department setting.Introduction
The assessment of disease severity and prediction of ad-
verse outcome in patients with acute respiratory tract infec-
tions (ARIs) is essential to improve patient management,
including therapeutic and diagnostic steps and site-of-care
decisions [1-3]. For this purpose, different blood bio-
markers have been evaluated to predict mortality in
smaller patient cohorts and critically ill patients, but re-
sults are still somewhat controversial in regard to type of
biomarker for specific ARI subpopulation and optimal cut-
off levels for clinical routine [4-10].* Correspondence: schuetzph@gmail.com
1University Department of Medicine, Kantonsspital Aarau, Tellstrasse, 5001
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unless otherwise stated.Procalcitonin (PCT), a precursor protein of calcitonin,
is currently one of the most frequently used infectious
disease biomarkers in clinical practice [11]. PCT levels
mirror severity and evolution of infection and are
thought to be associated with poor prognosis in patients
with sepsis and ARI [12]. Changes in PCT level in re-
sponse to therapeutic treatment have also been reported,
which suggests prognostic significance in a variety of
clinical settings [13,14]. However, there is a lack of clin-
ical data comparing PCT in different clinical settings
(primary care, emergency department (ED), intensive
care unit (ICU)) and across ARI diagnoses to aid in bet-
ter understanding its (prognostic) value in daily clinical
practice.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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value of admission PCT levels to predict treatment
failure and mortality alone in a large ARI patient
population across different settings, ARI diagnoses and
countries by performing an individual patient data
meta-analysis.Material and methods
Patients and setting
This analysis includes all patients from a previous indi-
vidual patient data meta-analysis [15]. The initial meta-
analysis was prespecified in collaboration with the
Cochrane Database of Systematic Reviews [16]. In brief,
the aim of the meta-analysis was to assess the safety and
efficacy of using PCT to guide initiation and duration of
antibiotic treatment in patients with ARI assigned to
routine PCT measurement or standard of care without
PCT measurement. This approach was used over a large
range of patients with varying severities of disease in dif-
ferent clinical settings. Patients with a clinical diagnosis
of either upper or lower ARI derived from 14 rando-
mised or quasi-randomised trials were included. Trials
focused exclusively on paediatric patients or on a pur-
pose other than initiation and duration of antibiotic
therapy were not included. Further details about identi-
fying suitable trials were published previously [16]. No
ethical approval was needed for this meta-analysis. Writ-
ten informed consent was obtained from all participants
within the initial trials, including consent to participate
in further analyses.Search for and identification of trials
The initial search was prespecified and published previ-
ously [16]. In brief, suitable trials were identified by a
formal search of the Cochrane Controlled Trials Registry
(CCTR), MEDLINE and Embase (all from their incep-
tion to May 2011), as well as reference lists of reports
describing such trials. In addition, conference proceed-
ings (from 2006 to 2011) of the Interscience Conference
on Antimicrobial Agents and Chemotherapy, the European
Congress of Clinical Microbiology and Infectious Dis-
ease, the American Thoracic Society, the American Asso-
ciation of Respiratory Care and the American College of
Chest Physicians were hand-searched. Trial registries
were checked and experts contacted for further eligible
trials. Two independent reviewers assessed trial eligibility
on basis of titles, abstracts, full-text reports and further
information obtained from investigators as needed. Fur-
ther, the protocol, case report forms and unedited data-
bases from investigators of all eligible trials were
requested. Data from each trial were first checked against
reported results, and queries were resolved with the prin-
cipal investigator, trial data manager or statistician.Aims and endpoints
The aim of the present analysis was to study associations
of admission PCT levels and adverse clinical outcomes.
In line with the initial Cochrane meta-analysis protocol
[16], the predefined primary endpoints were defined as
all-cause mortality and setting specific treatment failure
at 30 days. For the primary care setting, treatment failure
was defined as occurrence of at least one of the following
events: death, hospitalisation, ARI-specific complications
(for example, empyema for lower ARI, meningitis for
upper ARI), recurrent or worsening infection, and patients
reporting any symptoms of an ongoing respiratory infec-
tion (for example, fever, cough, dyspnoea) at 30-day
follow-up. For the ED setting, treatment failure was de-
fined as death, ICU admission, rehospitalisation after
index hospital discharge, ARI-associated complications
(for example, empyema or acute respiratory distress syn-
drome for lower ARI), or recurrent or worsening infection
within 30 days of follow-up. For the ICU setting, treat-
ment failure was defined as death within 30 days of
follow-up.
In regard to PCT as a baseline predictor, we used ini-
tial PCT levels corresponding to the PCT level drawn at
the primary care visit (primary care), ED admission (ED
trials) and ICU admission (ICU trials). In all trials, PCT
was measured using a rapid, sensitive assay with a func-
tional assay sensitivity of 0.06 μg/L (KRYPTOR PCT;
B∙R∙A∙H∙M∙S, Hennigsdorf, Germany) and an assay time
of less than 20 minutes. We used different a priori defined
PCT cutoffs (0.1 μg/L, 0.25 μg/L, 0.5 μg/L, 2.0 μg/L) that
correspond to cutoffs used in previous antibiotic stew-
ardship trials and also in practice guidelines on the use
of PCT.
Statistical analysis
We used descriptive statistics, including mean with stand-
ard deviation, median with interquartile range (IQR) and
frequencies, to describe the populations, as appropriate.
Patients were divided in two groups depending on
having experienced a treatment failure or not. Because
the rate of loss to follow-up in the different trials was
low (<10%), we assumed that patients lost to follow-up
did not undergo an event. This assumption was also
verified in a time-to-event analysis where we used cen-
soring for patients lost to follow-up.
For the primary endpoint of setting- and diagnosis-
specific treatment failure or all-cause mortality alone, we
calculated adjusted odds ratios (ORs) (with age and sex as
additional fixed effects) and 95% confidence intervals (CIs)
using multivariable hierarchical logistic regression. Discrim-
ination of PCT levels for treatment failure or mortality was
investigated by area under the receiver operating character-
istic (ROC) curve and 95% CIs. For the different clinical
settings (primary care, ED, ICU) and most prevalent ARI
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obstructive pulmonary disease (ECOPD), community ac-
quired pneumonia (CAP)), we calculated sensitivity and
specificity analyses. We used different clinically established
PCTcutoffs (0.1 μg/L, 0.25 μg/L, 0.5 μg/L, 2.0 μg/L) to esti-
mate risk prediction. If subgroups were too small, values
were labelled as ‘not applicable’. For graphical display, we
calculated Kaplan-Meier curves for time to death and time
to adverse outcome.
Tests were carried out at 5% significance levels. Analyses
were performed with STATA 12.1 software (StataCorp,
College Station, TX, USA).Results
Population
The study sample comprised all 4,211 intention-to-treat
patients (median age: 63 years, 54.2% male) with a final
diagnosis of ARI. Regarding the clinical setting, a total of
1,008 (23.9%) patients were from primary care, 2,605
(61.9%) from the ED and 598 (14.2%) from the ICU.
Overall, 864 patients (20.5%) had a treatment failure and
252 (6.0%) patients died. Baseline characteristics of theTable 1 Baseline characteristicsa
Parameter All (n =4,211) P
(n
Age (yr), median (IQR) 63 (44 to 76) 6
Men, n (%) 2,282 (54.2) 4
Clinical setting, n (%)
Primary care 1,008 (23.9) 3
Emergency department 2,605 (61.9) 4
ICU 598 (14.2) 1
Primary diagnosis
Total upper ARI, n (%) 549 (13.0) 1
Common cold 305 (7.2) 1
Rhinosinusitis, otitis 137 (3.3) 4
Pharyngitis, tonsillitis 107 (2.5) 3
Total lower ARI, n (%) 3,567 (84.7) 6
Community-acquired pneumonia 2,027 (48.1) 4
Hospital-acquired pneumonia 79 (1.9) 0
Ventilator-associated pneumonia 242 (5.7) 2
Acute bronchitis 531 (12.6) 1
Exacerbation of COPD 584 (13.9) 8
Exacerbation of asthma 30 (0.7) 5
Unspecified lower ARI 74 (1.8) 1
Other final diagnosis, n (%) 95 (2.3) 2
Procalcitonin overall (μg/L), mean, median
(SD, IQR)
2.5, 0.2 (11.4, 0.1 to 0.8) 4
aARI, Acute respiratory tract infection; COPD, Chronic obstructive pulmonary disease
Standard deviation.overall population and stratified based on the occurrence
of a treatment failure are summarized in Table 1.
Procalcitonin levels in different settings and acute
respiratory tract infections
As shown in Figure 1A, PCT levels significantly in-
creased with higher-acuity clinical settings (that is, pri-
mary care, ED, ICU). Similar results were found when
we looked at PCT levels in different types of ARI with
higher levels in more severe ARIs (that is, ECOPD, CAP,
ventilator-associated pneumonia) (Figure 1B).
Association of admission procalcitonin levels and adverse
outcome
Table 2 summarizes the results of logistic regression ana-
lysis as a measure of association and AUC as a measure of
discrimination for both endpoints: treatment failure and
mortality. PCT levels in ED patients were significantly as-
sociated with treatment failure (AUC: 0.64 (95% CI: 0.61,
0.67), adjusted OR: 1.85 (95% CI: 1.61, 2.12), P <0.001)
and mortality (AUC: 0.67 (95% CI: 0.63, 0.71), adjusted
OR: 1.82 (95% CI: 1.45, 2.29), P <0.001), whereas no sig-
nificant effect was seen in primary care or ICU patients. Inatients with treatment failure
=864)
Patients without treatment failure
(n =3,347)
3 (45 to 76) 63 (44 to 76)
38 (50.7) 1,844 (55.1)
23 (37.4) 685 (20.5)
10 (47.5) 2,195 (65.6)
31 (15.2) 467 (14.0)
85 (21.4) 364 (10.9)
05 (12.2) 200 (6.0)
6 (5.3) 91 (2.7)
4 (3.9) 73 (2.2)
54 (75.7) 2,913 (87.0)
30 (49.8) 1,597 (47.7)
(0) 79 (2.4)
0 (2.3) 222 (6.7)
05 (12.2) 426 (12.7)
0 (9.3) 504 (15.1)
(0.6) 25 (0.7)
4 (1.6) 60 (1.8)
5 (2.9) 70 (2.1)
.4, 0.2 (18.7, 0.1 to 1.2) 2.0, 0.2 (8.4, 0.1 to 0.8)
; ICU, Intensive care unit; IQR, Interquartile range; PCT, Procalcitonin; SD,
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Figure 1 Admission procalcitonin levels. (A) Procalcitonin (PCT)
levels stratified by setting (P = 0.0001). (B) PCT levels stratified by
diagnosis (P = 0.0001). ECOPD, Exacerbated chronic obstructive
pulmonary disease; ED, Emergency department; ICU, Intensive care
unit; CAP, Community-acquired pneumonia; PC, Primary care; VAP,
Ventilator-associated pneumonia.
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dict treatment failure (AUC: 0.58 (95% CI: 0.51, 0.64),
adjusted OR: 4.76 (95% CI: 1.27, 17.87), P = 0.021). Never-
theless, PCT did not deliver supplementary prognostic in-
formation in the overall upper ARI population. In lower
ARI, PCT was significantly associated with treatment fail-
ure (AUC: 0.57 (95% CI: 0.54, 0.59), adjusted OR: 1.40
(95% CI: 1.26, 1.55), P <0.001) and mortality (AUC: 0.71
(95% CI: 0.68, 0.74), adjusted OR: 2.13 (95% CI: 1.82,
2.49), P <0.001). In patients with acute bronchitis (AUC:
0.91 (95% CI: 0.88, 0.95), adjusted OR: 1.97 (95% CI: 0.20,
19.52), P = 0.561) and ECOPD (AUC: 0.79 (95% CI: 0.69,
0.90), adjusted OR: 6.12 (95% CI: 2.46, 15.18), P <0.001),
admission PCT levels were good predictors to identify pa-
tients at risk for mortality. Significantly different PCT
levels in patients with versus without events (treatment
failure or mortality) were also observed in ECOPD and
CAP, as detailed in Table 2. Figure 2 shows the results ofthe adjusted regression analysis for treatment failure and
mortality in the different populations studied.
PCT in the different cutoff ranges significantly separated
ED patients in regard to the time to treatment failure
(Figure 3A) and time to mortality (Figure 3B) (P <0.0001
and P = 0.02, respectively). Similar analyses did not show
significant results in the primary care and ICU settings
(data not shown). In the overall lower ARI population, as
well as in CAP patients, PCT also showed significant
separation in regard to the time to treatment failure
(P <0.0001 and P <0.01, respectively) and time to mortal-
ity (P <0.0001 and P <0.01, respectively) (Figure 4).
Tables 3 and 4 gives an overview of diagnostic mea-
sures (including sensitivity, specificity, negative predict-
ive values (NPVs) and positive predictive values (PPVs))
of PCT at different PCT cutoff levels. In primary care pa-
tients, a cutoff of 0.25 μg/L had a high PPV of 45.8%
(95% CI: 25.6, 67.2) and a high specificity of 98.1% (95%
CI: 96.8, 99.0) for treatment failure. At the same cutoff,
we found a high NPV of 89.2% (95% CI: 87.4, 90.8) and
a sensitivity of 65.6% (95% CI: 60.8, 70.2) for treatment
failure and a NPV of 97.5% (95% CI: 96.5, 98.3) and a
sensitivity of 72.5% (95% CI: 63.6, 80.3) for mortality in
ED patients. Similarly, in patients with lower ARIs, a low
PCT cutoff showed high levels of sensitivity, whereas
levels of specificity were higher with higher PCT cutoffs.
In patients with CAP, the NPV of PCT at the 0.1 and
0.25 μg/L cutoffs were high for treatment failure (85.5%
(95% CI: 80.2, 89.9) and 84.9% (95% CI: 81.9, 87.6)) as
well as for mortality (95.5% (95% CI: 91.8, 97.8) and
94.2% (95% CI: 92.2, 95.9)). For ICU patients, diagnostic
measures remained somewhat undetermined at all the
different PCT cutoffs.
Discussion
The findings of this analysis, which included a large
population with different types and severities of ARI
from previous randomised controlled trials, are three-
fold. First, we found an increase in PCT levels across
clinical settings and ARI diagnoses, demonstrating that
the current practice of using different cutoff levels in dif-
ferent clinical settings is mandatory. Second, initial PCT
levels were significantly associated with setting-specific
treatment failure and mortality in the overall population.
Third, the prognostic information derived from initial
PCT levels in primary care and ICU patients was rather
low, whereas in the ED setting and in ECOPD and bron-
chitis patients, admission PCT levels provided prognos-
tic information and thereby may improve initial risk
stratification in these patient populations.
An accurate and fast assessment of disease severity
and predictions regarding a patient’s clinical course po-
tentially assist patients and physicians with setting-
appropriate expectations regarding the illness. Such
Table 2 Procalcitonin levels at day 0 for prediction of severe adverse events in patients with acute respiratory infectiona
Event PCT (μg/L) in patients with
treatment failure
PCT (μg/L) in patients without
treatment failure
Adjusted OR
(95% CI)
AUC (95% CI) P-value
Clinical setting, mean, median (SD, IQR)
Primary care Treatment failure 0.26, 0.07 (2.22, 0.05 to 0.09) 0.14, 0.07 (0.83, 0.05 to 0.09) 1.12 (0.73, 1.72) 0.50 (0.46, 0.54) 0.606
Emergency department Treatment failure 5.26, 0.51 (17.86, 0.17 to 2.71) 1.85, 0.23 (8.09, 0.10 to 0.80) 1.85 (1.61, 2.12) 0.64 (0.61, 0.67) <0.001
Mortality 5.85, 0.54 (22.53, 0.21 to 3.17) 2.22, 0.24 (9.33, 0.10 to 0.96) 1.82 (1.45, 2.29) 0.67 (0.63, 0.71) <0.001
ICU Mortality 12.06, 1.15 (35.21, 0.33 to 6.34) 6.59, 1.36 (14.07, 0.37 to 5.07) 1.05 (0.81, 1.37) 0.50 (0.44, 0.56) 0.705
Primary diagnosis
Total upper ARI, n (%) Treatment failure 0.07, 0.06 (0.04, 0.05 to 0.08) 0.07, 0.06 (0.05, 0.04 to 0.08) 0.91 (0.40, 2.10) 0.50 (0.45, 0.55) 0.832
Common cold Treatment failure 0.07, 0.06 (0.03, 0.05 to 0.08) 0.06, 0.05 (0.03, 0.04 to 0.08) 4.76 (1.27, 17.87) 0.58 (0.51, 0.64) 0.021
Rhinosinusitis, otitis Treatment failure 0.06, 0.05 (0.03, 0.03 to 0.08) 0.08, 0.06 (0.08, 0.04 to 0.09) 0.18 (0.03, 0.96) 0.39 (0.29, 0.50) 0.045
Pharyngitis, tonsillitis Treatment failure 0.08, 0.07 (0.05, 0.06 to 0.10) 0.09, 0.08 (0.05, 0.06 to 0.11) 0.19 (0.02, 1.53) 0.42 (0.31, 0.54) 0.120
Total lower ARI, n (%) Treatment failure 5.64, 0.38 (21.20, 0.11 to 1.91) 2.34, 0.23 (8.97, 0.09 to 1.02) 1.40 (1.26, 1.55) 0.57 (0.54, 0.59) <0.001
Mortality 9.3, 0.95 (30.25, 0.30 to 5.11) 2.49, 0.22 (9.59, 0.09 to 1.04) 2.13 (1.82, 2.49) 0.71 (0.68, 0.74) <0.001
Acute bronchitis Treatment failure 0.10, 0.07 (0.11, 0.05 to 0.11) 0.22, 0.08 (0.93, 0.05 to 0.12) 0.77 (0.40, 1.48) 0.47 (0.41, 0.53) 0.430
Mortality 0.22, 0.22 (0.04, 0.19 to 0.24) 0.20, 0.08 (0.84, 0.05 to 0.11) 1.97 (0.20, 19.52) 0.91 (0.88, 0.95) 0.561
Exacerbation of COPD Treatment failure 0.40, 0.14 (1.30, 0.08 to 0.27) 0.23, 0.10 (0.67, 0.07 to 0.17) 1.94 (1.14, 3.32) 0.60 (0.53, 0.67) 0.015
Mortality 1.06, 0.25 (2.70, 0.18 to 0.62) 0.23, 0.10 (0.64, 0.07 to 0.18) 6.12 (2.46, 15.18) 0.79 (0.69, 0.90) <0.001
Community-acquired pneumonia Treatment failure 8.30, 1.00 (25.76, 0.28 to 5.19) 3.13, 0.41 (10.56, 0.17 to 1.57) 1.66 (1.44, 1.90) 0.61 (0.58, 0.64) <0.001
Mortality 10.66, 1.01 (32.95, 0.33 to 5.67) 3.53, 0.44 (11.63, 0.18 to 1.76) 1.69 (1.41, 2.04) 0.62 (0.58, 0.66) <0.001
Ventilator-associated pneumonia Mortality 4.27, 1.29 (6.43, 0.39 to 5.87) 5.34, 1.42 (11.81, 0.37 to 4.47) 1.08 (0.55, 2.12) 0.51 (0.38, 0.65) 0.817
aARI, Acute respiratory tract infection; AUC, Area under the curve; CI, Confidence interval; COPD, Chronic obstructive pulmonary disease; ICU, Intensive care unit; IQR, interquartile range; OR, odds ratio; PCT,
procalcitonin; SD, standard deviation. Statistically significant values are shown in bold.
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Figure 2 Multivariate regression analysis for estimation of predictive value of procalcitonin levels on admission stratified by adverse
events and mortality in different settings and diagnoses. *Treatment failure; ~Mortality; Adj., Adjusted; ARI, Acute respiratory tract infection;
CAP, Community-acquired pneumonia; CI, Confidence interval; ICU, Intensive care unit; COPD, Chronic obstructive pulmonary disease OR, Odds
ratio; VAP, Ventilator-associated pneumonia.
A 
B 
Figure 3 Association between time to severe adverse events and admission procalcitonin levels in emergency department patients.
(A) Time to treatment failure is significantly shorter in emergency department (ED) patients with higher procalcitonin (PCT) levels on admission.
(P <0.0001. (B) Time to death is significantly shorter in ED patients with higher PCT levels on admission (P <0.02). Treatment failure is defined as
death, ICU admission, rehospitalisation, complications or recurrent or worsening infection within 28 days.
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Figure 4 Association between time to severe adverse events and admission procalcitonin levels in lower acute respiratory tract
infection and community-acquired pneumonia patients. (A) Time to treatment failure is significantly shorter in lower acute respiratory tract
infection (ARI) patients with higher procalcitonin (PCT) levels on admission (P <0.0001). (B) Time to death is significantly shorter in lower ARI
patients with higher PCT levels on admission (P <0.0001). (C) Time to treatment failure is significantly shorter in patients with community-
acquired pneumonia (CAP) with higher PCT levels on admission (P <0.01). (D) Time to death is significantly shorter in patients with CAP with
higher PCT levels on admission (P <0.01). ED, Emergency department. Treatment failure is defined as death, ICU admission, rehospitalisation,
complications or recurrent or worsening infection within 28 days.
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cient use of health care and hospital resources and are
indispensable for choosing optimal therapeutic options
in the initial management of ARIs [17]. This includes de-
cisions regarding site of care, diagnostic evaluation and
assessment for appropriate early discharge [18].
The role of prognostication is also acknowledged by re-
spiratory infection guidelines, which recommend stratify-
ing patients with CAP on the basis of predicted risk for
mortality using validated risk scores (that is, the Pneumo-
nia Severity Index (PSI) or CURB-65 score) [19,20]. Clin-
ical risk scores are somewhat limited by practicality and
risk for miscalibration due to different patient populations,
and therefore they have only moderate operational charac-
teristics [21]. Also, these scores are validated only for CAP
and not for other ARIs. Thus, there is interest in add-
itional prognosticating mechanisms, throughout all clin-
ical settings and subgroups of ARIs, using newly available
biomarkers (such as PCT) that are objectively and rapidlymeasurable, as well as responsive to clinical recovery, and
that add relevant, reliable, real-time information.
The prognostic potential of PCT in patients with re-
spiratory infections has been evaluated in different stud-
ies, mainly in patients with CAP and sepsis. Most
studies have found PCT levels to be increased in pa-
tients not surviving their disease compared with survi-
vors, but with only moderate prognostic accuracy. In
line with our results, in a large CAP cohort in the
United States [22], the greatest benefit of PCT was
found in patients classified as high risk on the basis of
PSI score. Having a PCT <0.1 μg/L virtually excluded
mortality in these high-risk patients. In a Swiss study, re-
searchers found that initial PCT levels did not improve
clinical risk scores for mortality prediction [23]. Subse-
quent repeated measurements of PCT in this population
demonstrated improved clinical outcomes with falling
PCT levels. In addition, the study found that PCT was
more helpful in predicting treatment failure other than
Table 3 Procalcitonin cutoffs (0.1 and 0.25 μg/L) for risk prediction in different clinical settings and in various acute respiratory infection subgroupsa
Cutoff (μg/L) 0.1 μg/L 0.25 μg/L
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
PC
Treatment failure 19.8 (15.6, 24.6) 81.3 (78.2, 84.1) 33.3 (26.7, 40.5) 68.2 (64.9, 71.4) 3.41 (1.71, 6.01) 98.1 (96.8, 99.0) 45.8 (25.6, 67.2) 68.3 (65.2, 71.2)
ED
Treatment failure 86.1 (82.4, 89.3) 26.1 (24.2, 28.0) 17.9 (16.2, 19.7) 90.9 (88.4, 93.1) 65.6 (60.8, 70.2) 53.1 (51.0, 55.2) 20.8 (18.6, 23.1) 89.2 (87.4, 90.8)
Mortality 92.5 (86.2, 96.5) 25.0 (23.3, 26.7) 5.63 (4.65, 6.74) 98.6 (97.3, 99.3) 72.5 (63.6, 80.3) 51.2 (49.3, 53.2) 6.71 (5.4, 8.2) 97.5 (96.5, 98.3)
ICU
Mortality 95.2 (89.8, 98.2) 4.21 (2.43, 6.75) 24.6 (20.9, 28.7) 72.7 (49.8, 89.3) 80.8 (72.8, 87.3) 18.9 (15.1, 23.3) 24.7 (20.6, 29.2) 75.0 (65.1, 83.3)
Total lower ARI
Treatment failure 76.4 (72.9, 79.6) 28.2 (26.5, 29.9) 19.6 (18.1, 21.2) 83.9 (81.4, 86.1) 57.4 (53.5, 61.3) 52.8 (51.0, 54.7) 21.8 (19.9, 23.9) 84.4 (82.6, 86.0)
Mortality 94.5 (90.8, 97.0) 28.9 (27.4, 30.5) 8.89 (7.8, 10.1) 98.6 (97.7, 99.3) 78.1 (72.2, 83.2) 53.0 (51.3, 54.8) 10.9 (9.42, 12.4) 97.1 (96.2, 97.8)
Bronchitis
Treatment failure 28.6 (20.2, 38.2) 68.0 (63.3, 72.4) 18.1 (12.5, 24.8) 79.4 (74.9, 83.4) 3.81 (1.05, 9.47) 92.5 (89.5, 94.8) 11.1 (3.11, 26.1) 79.6 (75.7, 83.0)
Mortality 100 (15.8, 100) 68.9 (64.8, 72.9) 1.20 (0.15, 4.28) 100 (99.0, 100) 0.00 (0.00, 84.2) 93.2 (90.7, 95.2) 0.00 (0.00, 9.74) 99.6 (98.5, 100)
ECOPD
Treatment failure 60.0 (48.4, 70.8) 49.8 (45.3, 54.3) 16.0 (12.0, 20.6) 88.7 (84.4, 92.1) 27.5 (18.1, 38.6) 85.9 (82.5, 88.8) 23.7 (15.5, 33.6) 88.1 (84.9, 90.9)
Mortality 82.4 (56.6, 96.2) 49.4 (45.2, 53.6) 4.67 (2.57, 7.71) 98.9 (96.9, 99.8) 47.1 (23.0, 72.2) 85.0 (81.7, 87.8) 8.60 (3.79, 16.2) 98.2 (96.5, 99.2)
CAP
Treatment failure 92.5 (89.5, 94.8) 12.1 (10.5, 13.8) 22.2 (20.3, 24.2) 85.5 (80.2, 89.9) 77.1 (72.8, 81.0) 35.0 (32.6, 37.4) 24.3 (22.1, 26.7) 84.9 (81.9, 87.6)
Mortality 94.9 (90.9, 97.5) 11.8 (10.3, 13.4) 10.6 (9.20, 12.1) 95.5 (91.8, 97.8) 81.2 (75.1, 86.4) 33.9 (31.7, 36.1) 11.9 (10.2, 13.8) 94.2 (92.2, 95.9)
aARI, Acute respiratory tract infection; CAP, Community-acquired pneumonia; CI, Confidence interval; ECOPD, Exacerbated chronic obstructive pulmonary disease; ED, Emergency department; ICU, Intensive care unit;
NA, Not applicable due to small sample size; NPV, Negative predictive value; PC, Primary care; PCT, Procalcitonin; PPV, Positive predictive value.
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Table 4 Procalcitonin cutoffs (0.5 and 2.0 μg/L) for risk prediction in different clinical settings and in various acute respiratory infection subgroupsa
Cutoff (μg/L) 0.5 μg/L 2.0 μg/L
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
PC
Treatment failure 1.86 (0.69, 4.00) 98.7 (97.5, 99.4) 40.0 (16.3, 67.7) 68.0 (65.0, 70.9) NA NA NA NA
ED
Treatment failure 50.2 (45.3, 55.2) 68.6 (66.6, 70.6) 23.1 (20.3, 26.0) 88.0 (86.4, 89.6) 27.6 (23.3, 32.2) 85.9 (84.4, 87.4) 26.8 (22.7, 31.3) 86.4 (84.9, 87.8)
Mortality 52.5 (43.2, 61.7) 66.5 (64.6, 68.4) 7.05 (5.46, 8.94) 96.7 (95.7, 97.5) 28.3 (20.5, 37.3) 84.4 (82.9, 85.8) 8.08 (5.66, 11.1) 96.1 (95.1, 96.8)
ICU
Mortality 67.2 (58.2, 75.3) 30.8 (26.2, 35.7) 24.2 (19.8, 29.1) 74.1 (66.5, 80.7) 37.6 (29.1, 46.7) 58.2 (53.0, 63.2) 22.8 (17.3, 29.2) 73.9 (68.5, 78.8)
Total lower ARI
Treatment failure 44.9 (41.0, 48.8) 66.4 (64.7, 68.2) 23.5 (21.2, 26.0) 84.0 (82.4, 85.5) 24.4 (21.1, 27.9) 83.4 (82.0, 84.8) 25.3 (21.9, 28.9) 82.8 (81.3, 84.1)
Mortality 61.2 (54.7, 67.4) 66.2 (64.5, 67.8) 11.7 (9.97, 13.6) 95.9 (95.0, 96.7) 33.8 (27.8, 40.2) 83.1 (81.8, 84.4) 12.8 (10.3, 15.7) 94.5 (93.6, 95.3)
Bronchitis
Treatment failure 0.95 (0.02, 5.19) 96.0 (93.7, 97.7) 5.56 (0.14, 27.3) 79.7 (75.9, 83.1) NA NA NA NA
Mortality 0.00 (0.00, 84.2) 96.6 (94.7, 98.0) 0.00 (0.00, 18.5) 99.6 (98.6, 100) NA NA NA NA
ECOPD
Treatment failure 11.3 (5.28, 20.3) 93.8 (91.3, 95.8) 22.5 (10.8, 38.5) 86.9 (83.8, 89.6) 2.50 (0.30, 8.74) 98.8 (97.4, 99.6) 25.0 (3.19, 65.1) 86.4 (83.3, 89.1)
Mortality 29.4 (10.3, 56.0) 93.8 (91.5, 95.6) 12.5 (4.19, 26.8) 97.8 (96.2, 98.9) 5.88 (0.15, 28.7) 98.8 (97.5, 99.5) 12.5 (0.32, 52.7) 97.2 (95.5, 98.4)
CAP
Treatment failure 62.5 (57.7, 67.1) 54.1 (51.6, 56.6) 27.0 (24.2, 29.9) 84.2 (81.8, 86.4) 34.9 (30.4, 39.7) 77.7 (75.5, 79.7) 29.8 (25.8, 34.0) 81.5 (79.4, 83.4)
Mortality 64.0 (56.8, 70.7) 52.2 (49.8, 54.5) 12.8 (10.8, 15.1) 92.9 (91.2, 94.4) 36.0 (29.3, 43.2) 76.2 (74.1, 78.1) 14.3 (11.3, 17.7) 91.5 (90.0, 92.9)
aARI, Acute respiratory tract infection; CAP, Community-acquired pneumonia; CI, Confidence interval; ECOPD, Exacerbated chronic obstructive pulmonary disease; ED, Emergency department; ICU, Intensive care unit;
NA, Not applicable due to small sample size; NPV, Negative predictive value; PC, Primary care; PCT, Procalcitonin; PPV, Positive predictive value.
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Kutz et al. Critical Care  (2015) 19:74 Page 10 of 11mortality, such as ICU admission or CAP-related com-
plications. For these outcomes, PCT significantly im-
proved clinical risk scores. In another large CAP study,
done in Germany and including mostly low-risk patients,
researchers found that PCT was a fair predictor of mor-
tality and significantly improved clinical risk scores [24].
According to these studies, our findings are generally
congruent. In low-risk patients (primary care) with re-
spiratory infections, low PCT levels <0.1 μg/L correctly
identified patients at lower risk for treatment failure with
a high NPV. In higher-risk populations (CAP, ICU), in-
creased levels of PCT had high PPV mainly for mortality
prediction. In ED patients and in patients with lower
ARIs, PCT was a good predictor of treatment failure and
mortality.
Nonetheless, several limitations should be considered
when interpreting our results. First, we carried out a sec-
ondary analysis of a meta-analysis. It was designed to
focus on a different question, that is, whether using PCT
to guide initiation and duration of antibiotic treatment
in patients with ARIs in primary care, ED and ICUs is
safe and efficient in a broader patient population. Sec-
ond, we did not investigate the effect of repeated mea-
surements that might add supplementary prognostic
information to admission levels. Third, we focused only
on interventional trials as specified in the meta-analysis
protocol and did not include any observational data that
would potentially allow for larger sample sizes in the dif-
ferent subgroups and increases in the patient spectrum,
as in observational studies less rigorous exclusion cri-
teria usually apply. Fourth, we focused on adverse out-
comes as specified in the original trials, but we were not
able to look into some adverse outcomes, such as septic
shock and respiratory failure, among others. Fifth, clin-
ical risk scores such as CURB-65 and PSI for CAP and
Acute Physiology and Chronic Health Evaluation for
ICU patients were not routinely available and thus
were not included in this analysis. Similarly, we were
not able to obtain more detailed baseline data on all
patients, including comorbidities and other risk factors,
which would have allowed a more rigorous adjustment
in the statistical models. Although this study provides
new and clinically relevant information about the prog-
nostic value of initial admission PCT values in different
clinical setting and for different upper and lower ARIs,
it remains unclear whether an improved initial prog-
nostic assessment based on PCT level would translate
into better triage decisions and outcomes in patients.
Sixth, randomised controlled outcome studies need to
be conducted for patients with ARIs in the ED and
ICU to investigate whether real-life measurement of
PCT adds useful prognostic information and thereby
improves the daily clinical management and outcomes
of patients.Conclusions
This is the first large-scale study in which the prognostic
value of admission PCT levels has been investigated
throughout all clinical settings in the field of ARIs. PCT
levels mainly provide prognostic information for risk
stratification of patients in the ED setting and in patients
with low to moderate ARIs. Future randomised con-
trolled studies must address whether adding PCT to ini-
tial risk assessment can improve patient management
and prognostication.
Key messages
 We found an increase in PCT levels across the
clinical settings and ARI diagnoses, supporting the
current practice of using specific PCT cutoff levels
in different clinical settings.
 PCT levels are significantly associated with
treatment failure and mortality in the overall
population.
 The prognostic information of initial PCT levels in
primary care and ICU patients is rather low,
whereas admission PCT levels provide important
prognostic information in the ED setting and in
patients with low to moderate ARIs.
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